BeOne Medicines Ltd. (NASDAQ:ONC)
| Market Cap | $41.78B+12.4% |
| Revenue (ttm) | $6.61B+32.9% |
| Net Income | $915.57M+1235.6% |
| EPS | $8.57+379.2% |
| Shares Out | 106.86M |
| PE Ratio | 45.62 |
| Forward PE | 37.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 356,778 |
| Open | $391.75 |
| Previous Close | $399.70 |
| Day's Range | $389.77 - $399.17 |
| 52-Week Range | $253.95 - $424.73 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | $426.50(+9.10%) |
| Earnings Date | Feb 25, 2027 |
About ONC
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
6 firms rating ONC in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
$ONC stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ONC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ONC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ONC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ONC Revenue by Segment or Geography
| Product revenue gross | $2.44B | 56.31% |
| Product revenue net | $1.89B | 43.69% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ONC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ONC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ONC
| IBBiShares Biotechnology ETF | $261.45M |
| FBTFirst Trust NYSE Arca Biotechnology Index Fund | $108.97M |
| CGGOCapital Group Global Growth Equity ETF | $96.93M |
| CGGECapital Group Global Equity ETF | $26.16M |
| CGNGCapital Group New Geography Equity ETF | $19.23M |
| CGIECapital Group International Equity ETF | $16.48M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ONC’s recent data — informational, not investment advice
What’s Behind the Score
News check: Partnership expansion and Q3 earnings call suggest operational momentum; stock performance mention indicates market confidence in oncology focus.
Recent Insider Activity
Insider Score Trend Over Time
-39.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| CANC | Tema Oncology ETF | 4.34% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 3.84% |
| BBH | VanEck Biotech ETF | 3.00% |
| BGGG | Baillie Gifford Long Term Global Growth ETF | 2.89% |
| AGNG | Global X - Aging Population ETF | 2.82% |
| IBB | iShares Biotechnology ETF | 2.42% |
| XUSM | MarketDesk International Momentum ETF | 2.23% |
| NSI | National Security Emerging Markets Index ETF | 1.88% |
| ESIM | Eventide International ETF | 1.56% |
| EDGE.TO | Evolve Innovation Index Fund | 1.49% |
| BGEG | Baillie Gifford Emerging Markets ETF | 1.28% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.96% |
Weight is the stock’s share of each fund’s holdings.
